MedPath

Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice

Conditions
Non-Hyponatremia
SIADH
Non-SIADH Hyponatremia
Interventions
Registration Number
NCT01228682
Lead Sponsor
Otsuka Frankfurt Research Institute GmbH
Brief Summary

A Drug Utilisation Survey is performed to monitor and document the drug utilisation patterns of Samsca in routine medical practice.

A Post-Authorisation Safety Study is performed to collect information on the safety of Samsca when used in a real-life setting.

Detailed Description

Drug Utilisation Survey The drug utilisation analysis will describe the number of prescriptions, their distribution between different medical specialties, and indication for use as compared to the SmPC, patient age and patient gender distributions on a prescription level. In addition, the indication for use will be further categorised as

* SIADH

* Non-SIADH hyponatraemia

* Non-Hyponatraemia

Post-Authorisation Safety Study

Sodium levels at baseline and rate of sodium correction under therapy will be analysed. Safety findings will be described. The number of all non-serious and serious adverse events and the relative frequencies will be analysed in consideration of the risk categories below:

* Renal safety

* Aquaresis-related adverse effects

* Serum sodium correction rate

* Glucose homeostasis

* Cardiovascular safety and hemodynamics

* Respiratory system

* Drug metabolism and drug interactions

* Drug exposure during pregnancy

* Paediatric safety

Subgroup analyses will be performed for all safety findings by indication subgroups (SIADH and other indications), subgroups according to SIADH-underlying diseases, age groups, hepatically impaired patients and renally impaired patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Patients who are treated with Samsca
Read More
Exclusion Criteria
  • Patients who have not signed the data consent form
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients who are treated with Samsca.Tolvaptan-
Primary Outcome Measures
NameTimeMethod
Drug utilisation of Samsca stratified by prescribing medical specialty, indication for use, patient gender and patient age.3 years
Samsca sodium correction rates and adverse events in patients treated with Samsca3 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (47)

Otsuka Study location 39-001

๐Ÿ‡ฎ๐Ÿ‡น

Cuneo, Italy

Otsuka Study location 39.007

๐Ÿ‡ฎ๐Ÿ‡น

Florence, Italy

Otsuka Study location 39.005

๐Ÿ‡ฎ๐Ÿ‡น

Siena, Italy

Otsuka Study location 49.007

๐Ÿ‡ฉ๐Ÿ‡ช

Aachen, Germany

Otsuka Study location 45-001

๐Ÿ‡ฉ๐Ÿ‡ฐ

Copenhagen, Denmark

Otsuka Study location 47-001

๐Ÿ‡ณ๐Ÿ‡ด

Lorenskog, Norway

Otsuka Study location 34-013

๐Ÿ‡ช๐Ÿ‡ธ

Cordoba, Spain

Otsuka Study location 34-005

๐Ÿ‡ช๐Ÿ‡ธ

Madrid, Spain

Otsuka Study location 34.017

๐Ÿ‡ช๐Ÿ‡ธ

Majadahonda, Spain

Otsuka Study location 34-014

๐Ÿ‡ช๐Ÿ‡ธ

Castellon, Spain

Otsuka Study location 34-015

๐Ÿ‡ช๐Ÿ‡ธ

Castellon, Spain

Otsuka Study location 49-021

๐Ÿ‡ฉ๐Ÿ‡ช

Rostock, Germany

Otsuka Study location 49-019

๐Ÿ‡ฉ๐Ÿ‡ช

Regensberg, Germany

Otsuka study location 49-001

๐Ÿ‡ฉ๐Ÿ‡ช

Wuerzburg, Germany

Otsuka Study location 34-012

๐Ÿ‡ช๐Ÿ‡ธ

Sevilla, Spain

Otsuka Study location 34-007

๐Ÿ‡ช๐Ÿ‡ธ

Alicante, Spain

Otsuka Study location 34-002

๐Ÿ‡ช๐Ÿ‡ธ

Sevilla, Spain

Otsuka Study Location 46.001

๐Ÿ‡ธ๐Ÿ‡ช

Goeteborg, Sweden

Otsuka Study location 44.019

๐Ÿ‡ฌ๐Ÿ‡ง

Coventry, United Kingdom

Otsuka Study location 44.024

๐Ÿ‡ฌ๐Ÿ‡ง

Birmingham, United Kingdom

Otsuka Study location 44.003

๐Ÿ‡ฌ๐Ÿ‡ง

Durham, United Kingdom

Otsuka Study location 44-023

๐Ÿ‡ฌ๐Ÿ‡ง

Hartlepool, United Kingdom

Otsuka Study location 44.006

๐Ÿ‡ฌ๐Ÿ‡ง

Liverpool, United Kingdom

Otsuka Study location 44.016

๐Ÿ‡ฌ๐Ÿ‡ง

Liverpool, United Kingdom

Otsuka Study location 44-001

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, United Kingdom

Otsuka Study location 44.015

๐Ÿ‡ฌ๐Ÿ‡ง

Oldham, United Kingdom

Otsuka Study location 46-004

๐Ÿ‡ธ๐Ÿ‡ช

Karlstad, Sweden

Otsuka Study location 46.002

๐Ÿ‡ธ๐Ÿ‡ช

Linkรถping, Sweden

Otsuka Study location 46-003

๐Ÿ‡ธ๐Ÿ‡ช

Stockholm, Sweden

Otsuka Study location 44.005

๐Ÿ‡ฌ๐Ÿ‡ง

Kingston, United Kingdom

Otsuka Study location 44.021

๐Ÿ‡ฌ๐Ÿ‡ง

Nuneaton, United Kingdom

Otsuka Study location 44.007

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, United Kingdom

Otsuka Study location 44.013

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, United Kingdom

Otsuka Study location 44-027

๐Ÿ‡ฌ๐Ÿ‡ง

Oldham, United Kingdom

Otsuka Study location 44-025

๐Ÿ‡ฌ๐Ÿ‡ง

Preston, United Kingdom

Otsuka Study location 44.004

๐Ÿ‡ฌ๐Ÿ‡ง

Southampton, United Kingdom

Otsuka Study location 45-006

๐Ÿ‡ฉ๐Ÿ‡ฐ

Holstebro, Denmark

Otsuka Study location 49.016

๐Ÿ‡ฉ๐Ÿ‡ช

Dresden, Germany

Otsuka Study location 49.002

๐Ÿ‡ฉ๐Ÿ‡ช

Hamburg, Germany

Otsuka Study location 49.011

๐Ÿ‡ฉ๐Ÿ‡ช

Duesseldorf, Germany

Otsuka Study location 49.018

๐Ÿ‡ฉ๐Ÿ‡ช

Hannover, Germany

Otsuka Study Location 49-020

๐Ÿ‡ฉ๐Ÿ‡ช

Heidelberg, Germany

Otsuka Study location 49.012

๐Ÿ‡ฉ๐Ÿ‡ช

Hannover, Germany

Otsuka Study location 49.004

๐Ÿ‡ฉ๐Ÿ‡ช

Koeln, Germany

Otsuka Study location 49-024

๐Ÿ‡ฉ๐Ÿ‡ช

Heidelberg, Germany

Otsuka Study location 49.009

๐Ÿ‡ฉ๐Ÿ‡ช

Luebeck, Germany

Otsuka Study location 49.017

๐Ÿ‡ฉ๐Ÿ‡ช

Mannheim, Germany

ยฉ Copyright 2025. All Rights Reserved by MedPath